OSR (OSRH) subsidiary Vaximm said Wednesday that final data from a phase 2a trial showed that its investigational vaccine VXM01 in combination with avelumab "could offer meaningful clinical benefit" in patients with recurrent glioblastoma, a type of aggressive brain cancer.
The 25-patient trial also showed that the VXM01-avelumab combination therapy was well-tolerated and in line with previously reported data on avelumab alone, the company said.
The non-resected patient cohort showed a 12.0% objective response rate, while 12.0% of these patients showed a partial remission and 4.0% had stable disease, the company said.
The oral immunotherapy is designed to activate T-cells to attack tumor vasculature and cancer cells directly, the company said.
OSR shares climbed by nearly 130% in premarket trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。